Condition: High-grade Glioma · WHO Grade Ⅳ Glioma · Sponsor: Tcelltech Inc.
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4 Glioma.The study also plan to explore the Maximum Tolerated Dose (MTD) and determine the Recommended Phase II Dose (RP2D) of the CAR-T cell therapy.
This description comes directly from the study's public registry record.
Rui Feng, MD · +(86)13509312934 · fengrui@tcelltech.com
Xianzhen Chen, MM · +(86)18649725652 · chenxianzhen@tcelltech.com
Always discuss trial participation with your own doctor first.
| Mayo Clinic in Arizona | Phoenix, Arizona, United States | Recruiting |
| Mayo Clinic in Florida | Jacksonville, Florida, United States | Recruiting |
| Mayo Clinic in Rochester | Rochester, Minnesota, United States | Recruiting |
| Beijing Tiantan Hospital | Beijing, Beijing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06482905